Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Maartje Van Ruiten, Nienke E. van Trommel, Ekaterina S. Jordanova, John B. A. G. Haanen, Ton N. Schumacher, Gemma G. Kenter, Jossie Rotman, Marc van Beurden, Noor A. M. Bakker, Sanne Samuels, Bastiaan Nuijen, Karin E. de Visser, Tanja D. de Gruijl, Jos H. Beijnen, Henry Zijlmans, Joost H. van den Berg
Publikováno v:
Bakker, N A M, Rotman, J, Van Beurden, M, Zijlmans, H J M A A, Van Ruiten, M, Samuels, S, Nuijen, B, Beijnen, J, De Visser, K, Haanen, J, Schumacher, T, De Gruijl, T D, Jordanova, E S, Kenter, G G, Van Den Berg, J H & Van Trommel, N E 2021, ' HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN) : A phase I/II clinical trial ', Journal for Immunotherapy of Cancer, vol. 9, no. 8, 002547 . https://doi.org/10.1136/jitc-2021-002547
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer, 9(8):002547. BioMed Central
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer, 9(8):002547. BioMed Central
Journal for Immunotherapy of Cancer
BackgroundUsual vulvar intraepithelial neoplasia (uVIN) is a premalignancy caused by persistent infection with high-risk types of human papillomavirus (HPV), mainly type 16. Even though different treatment modalities are available (eg, surgical excis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb52bf3c6adfbc91bc3923e54b6cf18
https://research.vumc.nl/en/publications/835225f1-3bfb-4c3a-80d9-30f8b85de4ca
https://research.vumc.nl/en/publications/835225f1-3bfb-4c3a-80d9-30f8b85de4ca
Autor:
Martino Ambrosini, Sanne Duinkerken, Juan J. Garcia-Vallejo, Tanja D. de Gruijl, Lisa Rutte, Hakan Kalay, Sophie K. Horrevorts, Yvette van Kooyk
Publikováno v:
Duinkerken, S, Horrevorts, S K, Kalay, H, Ambrosini, M, Rutte, L, de Gruijl, T D, Garcia-Vallejo, J J & van Kooyk, Y 2019, ' Glyco-dendrimers as intradermal anti-tumor vaccine targeting multiple skin DC subsets ', Theranostics, vol. 9, no. 20, pp. 5797-5809 . https://doi.org/10.7150/thno.35059
Theranostics, 9, 5797-5809
Theranostics
Theranostics, 9(20), 5797-5809. Ivyspring International Publisher
Theranostics, 9, 20, pp. 5797-5809
Theranostics, 9, 5797-5809
Theranostics
Theranostics, 9(20), 5797-5809. Ivyspring International Publisher
Theranostics, 9, 20, pp. 5797-5809
Contains fulltext : 215802.pdf (Publisher’s version ) (Open Access) The human skin is an attractive anti-tumor vaccination site due to the vast network of dendritic cell (DC) subsets that carry antigens to the draining lymph nodes and stimulate tum
Autor:
Tom O'Toole, Yvette van Kooyk, Katarzyna Olesek, Joke M. M. den Haan, Floris J. Bikker, Eline S. Zwart, Geert Kazemier, Alsya J. Affandi, Helen J Pijffers, Joanna Grabowska, Ernesto Rodríguez, Tanja D. de Gruijl, Martino Ambrosini, Johannes Stöckl, Patrick P G Mulder, Kamran Nazmi, Gert Storm, Hakan Kalay, Miguel Lopez Venegas, Arnaud Barbaria, Alfons J.M. van den Eertwegh
Publikováno v:
Affandi, A J, Grabowska, J, Olesek, K, Venegas, M L, Barbaria, A, Rodríguez, E, Mulder, P P G, Pijffers, H J, Ambrosini, M, Kalay, H, O’Toole, T, Zwart, E S, Kazemier, G, Nazmi, K, Bikker, F J, Stöckl, J, van den Eertwegh, A J M, de Gruijl, T D, Storm, G, van Kooyk, Y & den Haan, J M M 2020, ' Selective tumor antigen vaccine delivery to human CD169 + antigen-presenting cells using ganglioside-liposomes ', Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 44, pp. 27528-27539 . https://doi.org/10.1073/pnas.2006186117
Proceedings of the National Academy of Sciences of the United States of America
Affandi, A J, Grabowska, J, Olesek, K, Lopez Venegas, M, Barbaria, A, Rodríguez, E, Mulder, P P G, Pijffers, H J, Ambrosini, M, Kalay, H, O'Toole, T, Zwart, E S, Kazemier, G, Nazmi, K, Bikker, F J, Stöckl, J, van den Eertwegh, A J M, de Gruijl, T D, Storm, G, van Kooyk, Y & den Haan, J M M 2020, ' Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes ', Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 44, pp. 27528-27539 . https://doi.org/10.1073/pnas.2006186117
Proceedings of the National Academy of Sciences of the United States of America, 117(44), 27528-27539. National Academy of Sciences
Proceedings of the National Academy of Sciences of the United States of America, 117(44), 27528-27539. National Acad Sciences
Proceedings of the National Academy of Sciences of the United States of America, 117(44), 27528. National Academy of Sciences
Proceedings of the National Academy of Sciences of the United States of America
Affandi, A J, Grabowska, J, Olesek, K, Lopez Venegas, M, Barbaria, A, Rodríguez, E, Mulder, P P G, Pijffers, H J, Ambrosini, M, Kalay, H, O'Toole, T, Zwart, E S, Kazemier, G, Nazmi, K, Bikker, F J, Stöckl, J, van den Eertwegh, A J M, de Gruijl, T D, Storm, G, van Kooyk, Y & den Haan, J M M 2020, ' Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes ', Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 44, pp. 27528-27539 . https://doi.org/10.1073/pnas.2006186117
Proceedings of the National Academy of Sciences of the United States of America, 117(44), 27528-27539. National Academy of Sciences
Proceedings of the National Academy of Sciences of the United States of America, 117(44), 27528-27539. National Acad Sciences
Proceedings of the National Academy of Sciences of the United States of America, 117(44), 27528. National Academy of Sciences
Significance Current immunotherapies only benefit a minority of all cancer patients, so it is necessary to develop other strategies to boost patients’ antitumor CD8+ T cell responses. Here, we formulated a liposomal vaccine carrier that selectively
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b5b0bd2f3d5b21a1135dc801af5210a
https://hdl.handle.net/1871.1/cd09ac07-dd23-4fd5-bd76-87f3083ea0b311245.1/3914c7d1-8c17-47bd-aaff-f6dbcfb36ea3
https://hdl.handle.net/1871.1/cd09ac07-dd23-4fd5-bd76-87f3083ea0b311245.1/3914c7d1-8c17-47bd-aaff-f6dbcfb36ea3
Autor:
Remco Bos, Ada M. Kruisbeek, Anneke W. Reurs, Saheli Sarkar, G. Kooij, Jorn Kaspers, Erik Manting, Helga E. de Vries, Haoxiao Zuo, Alwin Kamermans, Alex Karlsson-Parra, Marie-José van Lierop, Satwinder Kaur Singh, Tania Konry, Tanja D. de Gruijl
Publikováno v:
Cells, 10(11):3233. MDPI Multidisciplinary Digital Publishing Institute
Cells, Vol 10, Iss 3233, p 3233 (2021)
Cells
Cells, 10(11). MDPI Multidisciplinary Digital Publishing Institute
Zuo, H, van Lierop, M-J C, Kaspers, J, Bos, R, Reurs, A, Sarkar, S, Konry, T, Kamermans, A, Kooij, G, de Vries, H E, de Gruijl, T D, Karlsson-Parra, A, Manting, E H, Kruisbeek, A M & Singh, S K 2021, ' Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade ', Cells, vol. 10, no. 11, 3233 . https://doi.org/10.3390/cells10113233
Volume 10
Issue 11
Cells, Vol 10, Iss 3233, p 3233 (2021)
Cells
Cells, 10(11). MDPI Multidisciplinary Digital Publishing Institute
Zuo, H, van Lierop, M-J C, Kaspers, J, Bos, R, Reurs, A, Sarkar, S, Konry, T, Kamermans, A, Kooij, G, de Vries, H E, de Gruijl, T D, Karlsson-Parra, A, Manting, E H, Kruisbeek, A M & Singh, S K 2021, ' Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade ', Cells, vol. 10, no. 11, 3233 . https://doi.org/10.3390/cells10113233
Volume 10
Issue 11
DCP-001 is a cell-based cancer vaccine generated by differentiation and maturation of cells from the human DCOne myeloid leukemic cell line. This results in a vaccine comprising a broad array of endogenous tumor antigens combined with a mature dendri
Autor:
Dorian A. Stolk, Aram de Haas, Jana Vree, Sanne Duinkerken, Joyce Lübbers, Rieneke van de Ven, Martino Ambrosini, Hakan Kalay, Sven Bruijns, Hans J. van der Vliet, Tanja D. de Gruijl, Yvette van Kooyk
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Stolk, D A, de Haas, A, Vree, J, Duinkerken, S, Lübbers, J, van de Ven, R, Ambrosini, M, Kalay, H, Bruijns, S, van der Vliet, H J, de Gruijl, T D & van Kooyk, Y 2020, ' Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T-and iNKT Cell Responses ', Frontiers in Immunology, vol. 11, 990 . https://doi.org/10.3389/fimmu.2020.00990
Frontiers in Immunology
Frontiers in Immunology, 11:990
Stolk, D A, de Haas, A, Vree, J, Duinkerken, S, Lübbers, J, van de Ven, R, Ambrosini, M, Kalay, H, Bruijns, S, van der Vliet, H J, de Gruijl, T D & van Kooyk, Y 2020, ' Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T-and iNKT Cell Responses ', Frontiers in Immunology, vol. 11, 990 . https://doi.org/10.3389/fimmu.2020.00990
Frontiers in Immunology
Frontiers in Immunology, 11:990
In this study we developed a liposome-based vaccine containing palmitoylated synthetic long peptides (SLP) and alpha galactosylceramide (αGC) to specifically target dendritic cells (DC) for activation of both innate (invariant natural killer T-cells
Autor:
R. Eveline Li, Sjoerd T.T. Schetters, Floortje J. van Haften, Fabrizio Chiodo, Tanja D. de Gruijl, Yvette van Kooyk, Sanne Duinkerken
Publikováno v:
Duinkerken, S, Li, RJE, van Haften, F J, de Gruijl, TD, Chiodo, F, Schetters, STT & van Kooyk, Y 2019, ' Chemically engineered glycan-modified cancer vaccines to mobilize skin dendritic cells ', Current Opinion Chemical Biology, vol. 53, pp. 167-172 . https://doi.org/10.1016/j.cbpa.2019.10.001
Dendritic cell (DC)–targeting vaccines show great promise in increasing antitumor immunity. Glycan-engineered vaccines facilitate both DC targeting and increased uptake by DCs for processing and presentation to CD4+ and CD8+ T cells to induce tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49fbeb8814fc80080b2186c39597bd18
https://research.vumc.nl/en/publications/b0f27eba-339e-493e-969c-d95d284c4fd5
https://research.vumc.nl/en/publications/b0f27eba-339e-493e-969c-d95d284c4fd5
Autor:
Ada M. Kruisbeek, Tanja D. de Gruijl, Malika Koppes, Jorn Kaspers, Sandra van Wetering, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Saskia J. A. M. Santegoets, Yvonne den Hartog, Corien Eeltink, Satwinder Kaur Singh
Publikováno v:
Cancer Immunology, Immunotherapy
Cancer Immunology and Immunotherapy, 67(10), 1505-1518. Springer Science and Business Media Deutschland GmbH
van de Loosdrecht, A A, van Wetering, S, Santegoets, S J A M, Singh, S K, Eeltink, C M, den Hartog, Y, Koppes, M, Kaspers, J, Ossenkoppele, G J, Kruisbeek, A M & de Gruijl, T D 2018, ' A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia ', Cancer Immunology and Immunotherapy, vol. 67, no. 10, pp. 1505-1518 . https://doi.org/10.1007/s00262-018-2198-9
Cancer Immunology, Immunotherapy, 67(10), 1505-1518
Cancer Immunology and Immunotherapy, 67(10), 1505-1518. Springer Science and Business Media Deutschland GmbH
van de Loosdrecht, A A, van Wetering, S, Santegoets, S J A M, Singh, S K, Eeltink, C M, den Hartog, Y, Koppes, M, Kaspers, J, Ossenkoppele, G J, Kruisbeek, A M & de Gruijl, T D 2018, ' A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia ', Cancer Immunology and Immunotherapy, vol. 67, no. 10, pp. 1505-1518 . https://doi.org/10.1007/s00262-018-2198-9
Cancer Immunology, Immunotherapy, 67(10), 1505-1518
In elderly acute myeloid leukemia (AML) patients post-remission treatment options are associated with high comorbidity rates and poor survival. Dendritic cell (DC)-based immunotherapy is a promising alternative treatment strategy. A novel allogeneic
Autor:
Dieke van Dinther, Tanja D. de Gruijl, Yvette van Kooyk, Joke M. M. den Haan, Rieneke van de Ven, Dorian A. Stolk
Publikováno v:
van Dinther, D, Stolk, D A, van de Ven, R, van Kooyk, Y, de Gruij, T D & den Haan, J M M 2017, ' Targeting C-type lectin receptors : A high-carbohydrate diet for dendritic cells to improve cancer vaccines ', Journal of Leukocyte Biology, vol. 102, no. 4, pp. 1017-1034 . https://doi.org/10.1189/jlb.5MR0217-059RR
Journal of Leukocyte Biology
Journal of Leukocyte Biology
Review of in vivo targeting of tumor antigens to lectin receptors on antigen-presenting cells using antibodies or ligands may improve the antitumor efficacy of vaccines.
There is a growing understanding of why certain patients do or do not respo
There is a growing understanding of why certain patients do or do not respo
Autor:
Erik Hooijberg, Gert J. Ossenkoppele, Tanja D. de Gruijl, Jurjen M. Ruben, Arjan A. van de Loosdrecht, Theresia M. Westers, Hetty J. Bontkes
Publikováno v:
Cancer Immunology, Immunotherapy
Ruben, J M, Bontkes, H J, Westers, T M, Hooijberg, E, Ossenkoppele, G J, de Gruijl, T D & van de Loosdrecht, A A 2015, ' Differential capacity of human interleukin-4 and interferon-alpha monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen ', Cancer Immunology and Immunotherapy, vol. 64, no. 11, pp. 1419-1427 . https://doi.org/10.1007/s00262-015-1741-1
Cancer Immunology and Immunotherapy, 64(11), 1419-1427. Springer Science and Business Media Deutschland GmbH
Ruben, J M, Bontkes, H J, Westers, T M, Hooijberg, E, Ossenkoppele, G J, de Gruijl, T D & van de Loosdrecht, A A 2015, ' Differential capacity of human interleukin-4 and interferon-alpha monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen ', Cancer Immunology and Immunotherapy, vol. 64, no. 11, pp. 1419-1427 . https://doi.org/10.1007/s00262-015-1741-1
Cancer Immunology and Immunotherapy, 64(11), 1419-1427. Springer Science and Business Media Deutschland GmbH
Dendritic cells (DC) vaccination is a potent therapeutic approach for inducing tumor-directed immunity, but challenges remain. One of the particular interest is the induction of an immune response targeting multiple (unknown) tumor-associated antigen
Autor:
Madelon Q, Wentink, Henk M W, Verheul, Arjan W, Griffioen, Kenneth A, Schafer, Susan, McPherson, Richard J, Early, Hans J, van der Vliet, Tanja D, de Gruijl
Publikováno v:
Vaccine. 36(15)
Vascular endothelial growth factor (VEGF) is pivotal in tumor angiogenesis and therapies targeting the VEGF axis are widely used in the clinic for the treatment of cancer. We have developed a therapeutic vaccine targeting human (h)VEGFIn total 54 cyn